ABVC:NSD-ABVC Biopharma Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.06

Change

+0.01 (+0.95)%

Market Cap

USD 0.03B

Volume

0.05M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ABVC Stock Forecast & Price:
Based on the ABVC Biopharma Inc stock forecasts from 1 analysts, the average analyst target price for ABVC Biopharma Inc is USD 0.00 over the next 12 months. ABVC Biopharma Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of ABVC Biopharma Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, ABVC Biopharma Inc’s stock price was USD 1.06. ABVC Biopharma Inc’s stock price has changed by +12.77% over the past week, -45.64% over the past month and -79.01% over the last year.

No recent analyst target price found for ABVC Biopharma Inc
No recent average analyst rating found for ABVC Biopharma Inc

About ABVC Biopharma Inc (ABVC:NSD)

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast ca ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-06-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+1.44 (+0.51%)

USD73.48B 30.32 20.19
REGN Regeneron Pharmaceuticals Inc

-6.49 (-1.09%)

USD66.17B 8.57 6.35
MRNA Moderna Inc

+0.04 (+0.03%)

USD56.80B 4.26 2.94
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

-2.12 (-1.18%)

USD32.85B 55.02 44.86
BNTX BioNTech SE

+7.12 (+5.01%)

USD32.57B 2.40 1.28
RPRX Royalty Pharma Plc

-0.05 (-0.12%)

USD28.87B 31.29 15.41
GMAB Genmab AS

+0.73 (+2.30%)

USD21.17B 63.61 5.25
ARGX argenx NV ADR

+5.30 (+1.42%)

USD20.55B N/A -30.89
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ABVC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -68.73% 18% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.73% 18% F 14% F
Trailing 12 Months  
Capital Gain -79.22% 29% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.22% 29% F 16% F
Trailing 5 Years  
Capital Gain -47.00% 57% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.00% 57% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 56.07% 83% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.07% 83% B 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 156.97% 13% F 8% F
Risk Adjusted Return 35.72% 77% C+ 67% D+
Market Capitalization 0.03B 20% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.12 24% F 20% F
Price / Cash Flow Ratio -4.51 64% D 70% C-
EV/EBITDA -1.93 89% B+ 91% A-
Management Effectiveness  
Return on Equity -372.46% 7% F 3% F
Return on Invested Capital -133.17% 14% F 8% F
Return on Assets -92.24% 3% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.75 89% B+ 82% B-
Short Percent 0.31% 94% A 85% B
Beta 0.49 87% B+ 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector